The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Onychomycosis


Psychiatry related information on Onychomycosis

  • CONCLUSION: In conclusion, treatment decision-making tools (e.g. an illustrated booklet or CD-ROM presenting each type of onychomycosis and criteria to be considered before selecting treatment regimen) would be valuable supports for the successful treatment of onychomycoses [6].

High impact information on Onychomycosis


Chemical compound and disease context of Onychomycosis


Biological context of Onychomycosis


Gene context of Onychomycosis

  • We aimed to establish the prevalence, clinical characteristics, and organisms causing onychomycosis in SLE patients compared with controls [19].
  • Polymerase chain reaction for diagnosis of dermatophyte and Scytalidium spp. onychomycosis [20].
  • METHODS: Nail specimens from 10 patients with onychomycosis due to T. rubrum were cultured and five colonies per culture plate were selected for molecular strain typing [21].
  • Samples were obtained when abnormal nails were found: distal and lateral subungual onychomycosis (DLSO), white superficial, proximal subungual (PSO), endonyx, and total dystrophic (TDO) [19].
  • A combination of alkali treatment and proteinase K digestion was used to solubilize nail samples from patients with onychomycosis treated orally with terbinafine [22].

Analytical, diagnostic and therapeutic context of Onychomycosis


  1. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Stevens, D.A., Greene, S.I., Lang, O.S. Arch. Intern. Med. (1991) [Pubmed]
  2. Terbinafine. An update of its use in superficial mycoses. McClellan, K.J., Wiseman, L.R., Markham, A. Drugs (1999) [Pubmed]
  3. Superficial mycoses. Taplin, D. J. Invest. Dermatol. (1976) [Pubmed]
  4. Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Lackner, T.E., Clissold, S.P. Drugs (1989) [Pubmed]
  5. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Velthuis, P.J., Nijenhuis, M. Br. J. Dermatol. (1995) [Pubmed]
  6. Treatment options--development of consensus guidelines. Lecha, M., Effendy, I., Feuilhade de Chauvin, M., Di Chiacchio, N., Baran, R. Journal of the European Academy of Dermatology and Venereology : JEADV. (2005) [Pubmed]
  7. Congestive heart failure associated with itraconazole. Ahmad, S.R., Singer, S.J., Leissa, B.G. Lancet (2001) [Pubmed]
  8. Onychomycosis: pathogenesis, diagnosis, and management. Elewski, B.E. Clin. Microbiol. Rev. (1998) [Pubmed]
  9. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Walzer, P.D., Ashbaugh, A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  10. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Haria, M., Bryson, H.M. Drugs (1995) [Pubmed]
  11. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Kovarik, J.M., Mueller, E.A., Zehender, H., Denouël, J., Caplain, H., Millerioux, L. Antimicrob. Agents Chemother. (1995) [Pubmed]
  12. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Jue, S.G., Dawson, G.W., Brogden, R.N. Drugs (1985) [Pubmed]
  13. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Elewski, B.E., Hay, R.J. Clin. Infect. Dis. (1996) [Pubmed]
  14. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. Savin, R.C., Drake, L., Babel, D., Stewart, D.M., Rich, P., Ling, M.R., Breneman, D., Scher, R.K., Martin, A.G., Pariser, D.M., Pariser, R.J., Ellis, C.N., Kang, S., Friedman, D., Katz, H.I., McDonald, C.J., Muglia, J., Webster, G., Elewski, B.E., Leyden, J.J., Bucko, A.D., Tschen, E.H., Hanifin, J.M., Morman, M.R., Hilbert, J. J. Am. Acad. Dermatol. (1998) [Pubmed]
  15. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. De Doncker, P., Decroix, J., Piérard, G.E., Roelant, D., Woestenborghs, R., Jacqmin, P., Odds, F., Heremans, A., Dockx, P., Roseeuw, D. Archives of dermatology. (1996) [Pubmed]
  16. New antifungal agents. Gupta, A.K., Tomas, E. Dermatologic clinics. (2003) [Pubmed]
  17. Safety of oral terbinafine for toenail onychomycosis. Pollak, R., Billstein, S.A. Journal of the American Podiatric Medical Association. (1997) [Pubmed]
  18. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. Warshaw, E.M., Bowman, T., Bodman, M.A., Kim, J.J., Silva, S., Mathias, S.D. Journal of the American Podiatric Medical Association. (2003) [Pubmed]
  19. Onychomycosis in systemic lupus erythematosus: a case control study. Tlacuilo-Parra, A., Guevara-Gutierrez, E., Mayorga, J., Garcia-De La Torre, I., Salazar-Paramo, M. J. Rheumatol. (2003) [Pubmed]
  20. Polymerase chain reaction for diagnosis of dermatophyte and Scytalidium spp. onychomycosis. Menotti, J., Machouart, M., Benderdouche, M., Cetre-Sossah, C., Morel, P., Dubertret, L., Derouin, F., Feuilhade De Chauvin, M., Lacroix, C. Br. J. Dermatol. (2004) [Pubmed]
  21. Molecular strain typing of Trichophyton rubrum indicates multiple strain involvement in onychomycosis. Yazdanparast, A., Jackson, C.J., Barton, R.C., Evans, E.G. Br. J. Dermatol. (2003) [Pubmed]
  22. Determination of terbinafine in nail samples during systemic treatment for onychomycoses. Dykes, P.J., Thomas, R., Finlay, A.Y. Br. J. Dermatol. (1990) [Pubmed]
  23. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Chien, R.N., Yang, L.J., Lin, P.Y., Liaw, Y.F. Hepatology (1997) [Pubmed]
  24. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. Odom, R.B., Aly, R., Scher, R.K., Daniel, C.R., Elewski, B.E., Zaias, N., DeVillez, R., Jacko, M., Oleka, N., Moskovitz, B.L. J. Am. Acad. Dermatol. (1997) [Pubmed]
  25. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. Drake, L., Babel, D., Stewart, D.M., Rich, P., Ling, M.R., Breneman, D., Scher, R.K., Martin, A.G., Pariser, D.M., Pariser, R.J., Ellis, C.N., Kang, S., Katz, H.I., McDonald, C.J., Muglia, J., Savin, R.C., Webster, G., Elewski, B.E., Leyden, J.J., Bucko, A.D., Tschen, E.H., Hanifin, J.M., Morman, M.R., Shupack, J.L., Greer, D.L. J. Am. Acad. Dermatol. (1998) [Pubmed]
  26. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine. Elewski, B.E. Archives of dermatology. (1997) [Pubmed]
WikiGenes - Universities